May 16, 2019 / 12:08 PM / 2 months ago

BRIEF-Parvus Therapeutics Enters Into Collaboration & License Agreement With Genentech To Develop Navacim Therapeutics For Treatment Of Autoimmune Diseases

May 16 (Reuters) - Roche Holding AG:

* PARVUS THERAPEUTICS ENTERS INTO COLLABORATION & LICENSE AGREEMENT WITH GENENTECH TO DEVELOP NAVACIM THERAPEUTICS FOR TREATMENT OF AUTOIMMUNE DISEASES

* PARVUS THERAPEUTICS - PARVUS ELIGIBLE TO RECEIVE UPFRONT AND MILESTONE PAYMENTS EXCEEDING $800 MILLION PLUS ROYALTIES ON NET SALES

* PARVUS THERAPEUTICS - GENENTECH WILL BE RESPONSIBLE FOR CLINICAL DEVELOPMENT FROM PHASE II AND BEYOND

* PARVUS - WILL RECEIVE UNDISCLOSED UPFRONT PAYMENT AND IS ELIGIBLE TO RECEIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION MILESTONE PAYMENTS

* PARVUS - ALSO ELIGIBLE TO RECEIVE CERTAIN ADDITIONAL MILESTONE PAYMENTS IN OTHER DISEASE AREAS, AS WELL AS ROYALTIES ON NET SALES OF PRODUCTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below